Kori L Brewer

ECU, Brody School of Medicine, Emergency Medicine

Scopus Publication Detail

The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.

Intravenous ketorolac vs intravenous prochlorperazine for the treatment of migraine headaches

Michael B. Seim; Juan A. March; Kathleen A. Dunn (Profiled Author: Juan A March)

Academic Emergency Medicine. 1998;5(6):573-576.

Objective: To compare IV ketorolac with IV prochlorperazine as the initial treatment of migraine headaches in the ED. Methods: A prospective, double-blind comparison study was performed, using a convenience sample of 64 patients suffering from migraine headaches presenting to the ED at a tertiary care university teaching hospital. Patients were randomly assigned to receive either 10 mg of prochlorperazine IV or 30 mg of ketorolac IV. Patients scored the severity of their headaches using a 10-cm visual analog pain scale. An initial mark was made on the scale at the time of entry into the study and later another mark was made on a new unmarked pain scale i hour after medication administration. Changes in pain scores within each treatment group and between groups were analyzed using the Wilcoxon rank sum test. Results: Prior to treatment, the patients assigned to receive prochlorperazine had a median score of 9.2 cm (mean ± SD pain score of 8.3 cm ± 2.1 cm), while the patients receiving ketorolac had a median score of 9.0 (mean pain score of 8.4 cm ± 1.7 cm). There was no significant difference between the pain scores of the participants in the 2 groups prior to treatment (p = 0.80). One hour after medication administration, the patients in the prochlorperazine group had a median score of 0.5 cm (mean 2.1 ± 3.2 cm), while those patients receiving ketorolac had a median pain score of 3.9 (mean 4.0 ± 3.3 cm). The decrease in pain score was significant for both groups of patients (p = 0.0001). The change in pain score for the patients in the prochlorperazine group (median 7.1) was significantly greater than the change in pain score for the patients in the ketorolac group (median 4.0; p = 0.04). Conclusion: Although both drugs were associated with a significant reduction in pain scores, benefit over a placebo agent was not tested. Furthermore, the patients who received prochlorperazine IV for migraine headaches had a statistically significant greater decrease in their pain scores than did those receiving ketorolac IV.

PMID: 9660282    

Scientific Context

This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.